www.genengnews.com Open in urlscan Pro
141.193.213.20  Public Scan

Form analysis
4 forms found in the DOM

GET https://www.genengnews.com/

<form method="get" class="td-search-form" action="https://www.genengnews.com/">
  <!-- close button -->
  <div class="td-search-close">
    <span><i class="td-icon-close-mobile"></i></span>
  </div>
  <div role="search" class="td-search-input">
    <span>Search</span>
    <input id="td-header-search-mob" type="text" value="" name="s" autocomplete="off">
  </div>
</form>

POST #

<form id="loginForm" action="#" method="post">
  <div class="td-login-inputs"><input class="td-login-input" autocomplete="username" type="text" name="login_email" id="login_email" value="" required=""><label for="login_email">your username</label></div>
  <div class="td-login-inputs"><input class="td-login-input" autocomplete="current-password" type="password" name="login_pass" id="login_pass" value="" required=""><label for="login_pass">your password</label></div>
  <input type="button" name="login_button" id="login_button" class="wpb_button btn td-login-button" value="Login">
</form>

POST #

<form id="forgotpassForm" action="#" method="post">
  <div class="td-login-inputs"><input class="td-login-input" type="text" name="forgot_email" id="forgot_email" value="" required=""><label for="forgot_email">your email</label></div>
  <input type="button" name="forgot_button" id="forgot_button" class="wpb_button btn td-login-button" value="Send My Password">
</form>

GET https://www.genengnews.com/

<form method="get" class="td-search-form" action="https://www.genengnews.com/">
  <div role="search" class="td-head-form-search-wrap">
    <input id="td-header-search" type="text" value="" name="s" autocomplete="off"><input class="wpb_button wpb_btn-inverse btn" type="submit" id="td-header-search-top" value="Search">
  </div>
</form>

Text Content

genprowebdirectory

Facebook Linkedin RSS Twitter Youtube

 * GEN Edge
   * Featured News
   * Multimedia
 * News
   * Insights
 * Topics
   * Artificial Intelligence
   * Bioprocessing
   * Cancer
   * Drug Discovery
   * Genome Editing
   * Infectious Diseases
   * OMICs
   * Translational Medicine
 * Magazine
   * Browse Issues
   * Subscribe
 * Multimedia
   * Summits
   * Webinars
   * GEN Live
   * Learning Labs
   * Podcasts
 * Resources
   * A-Lists
   * eBooks/Perspectives
   * Tutorials
   * Peer-Reviewed Journals
     * GEN Biotechnology
     * Re:Gen Open
   * New Products
   * Conference Calendar
 * Subscribe
   * Get GEN Magazine
   * Get GEN eNewsletters


Search

Facebook Linkedin RSS Twitter Youtube

Sign in
Welcome! Log into your account

your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password

your email
A password will be e-mailed to you.


GEN – GENETIC ENGINEERING AND BIOTECHNOLOGY NEWS

 * GEN Edge
   * Featured News
   * Multimedia
 * News
   * Insights
 * Topics
   * Artificial Intelligence
   * Bioprocessing
   * Cancer
   * Drug Discovery
   * Genome Editing
   * Infectious Diseases
   * OMICs
   * Translational Medicine
 * Magazine
   * Browse Issues
   * Subscribe
 * Multimedia
   * Summits
   * Webinars
   * GEN Live
   * Learning Labs
   * Podcasts
 * Resources
   * A-Lists
   * eBooks/Perspectives
   * Tutorials
   * Peer-Reviewed Journals
     * GEN Biotechnology
     * Re:Gen Open
   * New Products
   * Conference Calendar
 * Subscribe
   * Get GEN Magazine
   * Get GEN eNewsletters




FEATURED


OVARIAN CANCER: EARLY DETECTION WITH AI-AIDED BIOMARKER ANALYSIS


RHEUMATOID ARTHRITIS STUDY IDS MACROPHAGES THAT COULD HASTEN DIAGNOSIS,
TREATMENT


DISRUPTING THE GUT’S CLOCK COULD FUEL COLORECTAL CANCER


NEW BRAIN-MAPPING TOOL, START, RESOLVES CONNECTIVITY AT THE RESOLUTION OF
TRANSCRIPTOMIC CELL TYPES


PRIME MEDICINE INKS UP-TO-$3.5B COLLABORATION WITH BMS, NARROWS PIPELINE

RSS

LATEST NEWS


OMICs


NEW BRAIN-MAPPING TOOL, START, RESOLVES CONNECTIVITY AT THE RESOLUTION OF
TRANSCRIPTOMIC CELL TYPES


Cancer


DISRUPTING THE GUT’S CLOCK COULD FUEL COLORECTAL CANCER



Bioprocessing


PIRAMAL PHARMA SOLUTIONS PLANS $80M EXPANSION FOR KENTUCKY FACILITY


Translational Medicine


RHEUMATOID ARTHRITIS STUDY IDS MACROPHAGES THAT COULD HASTEN DIAGNOSIS,
TREATMENT


Cancer


CHECKPOINT INHIBITORS MAY BE IMPROVED BY METABOLIC REPROGRAMMING OF T CELLS



Load More



LATEST INSIGHTS


ACCELERATE SCREENING AND CHARACTERIZATION OF PROTEINS




ESTIMATING THE MELTING TEMPERATURE OF THERAPEUTIC NANOBODIES




MIRAI BIO FOUNDED TO PROVIDE FULLY INTEGRATED END-TO-END GENETIC MEDICINE
DEVELOPMENT




IMPROVING CAR-T CELL EFFICACY VIA NEW MANUFACTURING PROCESS




TRANSFORMING UPSTREAM BIOPRODUCTION WITH PROCESS INTENSIFICATION




UNLOCKING OPPORTUNITIES IN UPSTREAM VIRAL VECTOR MANUFACTURING


More Like This

LATEST FROM GEN EDGE


OMICs


STOCKWATCH: TURNAROUND LIFTS GENEDX STOCK 3,600%, WITH PROFITABILITY NEAR


Drug Discovery


PFIZER WITHDRAWS SCD DRUG OXBRYTA AFTER EMA DISCLOSES 16 DEATHS IN...


Artificial Intelligence


NVIDIA LAUNCHES AI REFERENCE WORKFLOW FOR DRUG DISCOVERERS




LATEST A-LISTS


A-Lists


TOP 50 NIH-FUNDED INSTITUTIONS OF 2024


A-Lists


TOP 10 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS 2024


A-Lists


8 CONTRACT DEVELOPMENT AND MANUFACTURING COMPANIES TO WATCH



FEATURED VIDEOS

John Sterling, GEN’s Editor-in-Chief, has been attending BPI since its
inception, 20 years ago! Here, he took a minute away from the talks and posters
to join Julianna LeMieux, PhD, Deputy Editor-in-Chief—who was at BPI for her
second time—to talk about the first day of the meeting, the sessions they
attended, and the trends that they are noticing. John also reflects on 20 years
in the industry.



BIOPROCESSING IN BOSTON: GEN REPORTS LIVE FROM BPI 2024

Avak Kahvejian, PhD, leads a team that invents and launches new therapeutic
platforms as a general partner at Flagship Pioneering, the venture/accelerator
giant. Speaking on GEN’s “Close to the Edge” video interview series, Kahvejian
recounted his career from life sciences executive to a life sciences inventor,
entrepreneur, and CEO, who has founded more than 10 companies.

  After earning his BSc and PhD degrees from McGill University, Kahvejian held
positions at Helicos BioSciences—a next-generation sequencing pioneer where he
developed and commercialized the world’s first single-molecule DNA
sequencer—before joining Flagship in 2011. Based in Cambridge, MA, Flagship has
built a primary portfolio of companies focused on life sciences or “human
health” and sustainability, as well as on AI. The firm’s best-known companies
that have grown from startups include Moderna, the mRNA vaccine giant that has
brought several COVID-19 vaccines to approval, and Generate:Biomedicines, a
developer of therapeutics based on de novo protein generation. Generate was
among multiple high-value public and private companies created by Kahvejian and
his team. Other companies include:
 * Seres Therapeutics, developer of the first microbiome therapy platform
 * Ring Therapeutics, a developer of gene therapies based on its commensal
   virome platform
 * Cellarity, which aims to design medicines targeting the full cellular and
   molecular complexity of disease as opposed to a single molecular target
 * Abiologics, a developer of programmable medicines combining generative
   artificial intelligence and high throughput chemical protein synthesis (it
   emerged from stealth mode in July)
 * Cygnal Therapeutics, now part of Sonata Therapeutics, whose Network
   Medicines™ reprogram diseased cells to become “coordinators of cure” by
   releasing a defined array of signals designed to precisely coordinate
   multicellular networks to drive disease resolution

Kahvejian also discussed the lessons to be learned from Laronde, the circular
RNA therapy developer where he served as a board member and founding CEO months
before it announced an eye-popping $440 million Series B financing in 2021.
Laronde merged with Senda Biosciences last year to form Sail Biosciences,
following conflicts over the reliability of data from historic GLP-1 experiments
for the company’s therapeutic peptide. In a wide-ranging conversation, Kahvejian
also offered insights into Flagship’s fundamental strategy for selecting
companies, how early in the business cycle Flagship invests in a startup, and
how long Flagship likes to stay invested in a company. Kahvejian discussed the
rise of AI and weighed in on its potential risk of hype and potential benefit of
delivering the hope of finally addressing longtime challenges, such as the cost
and time it takes to develop new drugs.


AVAK KAHVEJIAN, PHD, RECOUNTS HIS JOURNEY FROM SEQUENCING PIONEER TO FLAGSHIP
GENERAL PARTNER ON “CLOSE TO THE EDGE”

More Like This

TOUCHING BASE PODCAST


Touching Base


DNA DAY: DEEP DIVE



Touching Base


HOW BIOTECHS ARE PLUGGING AI INTO DRUG DISCOVERY PROBLEMS


Load more


LATEST WEBINARS, GEN LIVE, VIRTUAL EVENTS, EBOOKS, & PODCASTS

Upcoming



NAVIGATING GMP MANUFACTURING WORKFLOWS FOR RNA-LNP THERAPEUTICS


In this GEN webinar, David Sokolowski and Ingram Vargas will share strategies
for successfully navigating evolving manufacturing workflows, processes, and
technologies for RNA vaccines and therapies.


ALZHEIMER’S DISEASE: EARLY DETECTION AND MULTI-ETIOLOGY INSIGHTS FROM
BLOOD-BASED IMMUNOASSAYS




STRATEGIES FOR SCREENING AND CHARACTERIZING TARGETED COVALENT INHIBITORS FROM
DISCOVERY TO IND




THERAPEUTIC ANTIBODY DISCOVERY: SELECTING EFFECTIVE CANDIDATES FOR EMERGING
VIRAL THREATS




HOW ORGANOIDS ARE ACCELERATING DRUG DISCOVERY: A DISCUSSION OF CURRENT RESEARCH,
CHALLENGES, AND FUTURE DIRECTIONS




THE STATE OF AI IN DRUG DISCOVERY 2024




MAGAZINE


GEN: SEPTEMBER 2024

Even though biomanufacturing experiences ups and downs in demand, it recognizes
what is constant—the need to adapt. For example, as the CEO of a leading CDMO
quoted in this issue of GEN observes, biotech and biopharma clients appear to be
tightening their budgets and pruning their pipelines. And yet long-term trends
look promising, especially given the growing importance of therapeutic
modalities. In this issue, both near-term challenges and long-term opportunities
are discussed in our A-List of Top 10 CDMOs. But what should biomanufacturers do
when demand surges? That’s covered in this issue, too. And, as always, GEN
addresses developments of various kinds. Besides offering biomanufacturing
coverage, this issue presents articles on gene therapy, digital twins, phage
therapy, and biomarker development.

Read Magazine

LATEST ARTICLES BY TOPIC


IDENTIFY OPTIMAL BIOLOGIC CANDIDATES IN EARLY-STAGE DEVELOPABILITY ASSESSMENT




IMPROVE SANGER SEQUENCING WORKFLOW EFFICIENCY WITH A NEW BROWSER-BASED CAPILLARY
ELECTROPHORESIS...




WORKING WITH REGULATORS TO GET GENE THERAPIES TO MORE PATIENTS




PIRAMAL PHARMA SOLUTIONS PLANS $80M EXPANSION FOR KENTUCKY FACILITY




CHECKPOINT INHIBITORS MAY BE IMPROVED BY METABOLIC REPROGRAMMING OF T CELLS




IVF COULD BE IMPROVED IF DISUSED “PAUSE BUTTON” IN EMBRYOS IS...



LATEST CORONAVIRUS NEWS


Coronavirus


ARTIFICIAL LYMPHOID ORGANS COULD HELP PREDICT BOOSTER VACCINE EFFICACY


Coronavirus


SUPERBUGS IN HOSPITALS COULD BE TRACKED WITH PAN-PATHOGEN DEEP SEQUENCING


Coronavirus


COVID-19 NASAL VACCINE RESULTS SHOW PROGRESS TOWARD TRANSMISSION-HALTING
APPROACH




RECENTLY FEATURED


NEW BRAIN-MAPPING TOOL, START, RESOLVES CONNECTIVITY AT THE RESOLUTION OF
TRANSCRIPTOMIC CELL TYPES




DISRUPTING THE GUT’S CLOCK COULD FUEL COLORECTAL CANCER




OVARIAN CANCER: EARLY DETECTION WITH AI-AIDED BIOMARKER ANALYSIS




PIRAMAL PHARMA SOLUTIONS PLANS $80M EXPANSION FOR KENTUCKY FACILITY







SUBSCRIBE TO
GEN DAILY

*



READ THE DIGITAL EDITION






EXPLORE

 * About GEN
 * Contact GEN
 * GEN Staff
 * Editorial Guidelines
 * Reprints and Permissions
 * Scientific Advisory Board

ADVERTISE

 * Media Kit and Planning Calendar
 * Advertising Terms and Conditions

RESOURCES

 * Get the GEN Magazine
 * Get the GEN Email Newsletter
 * Inside Precision Medicine
 * Privacy Policy

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up
×

By clicking “Accept All Cookies”, you agree to the storing of cookies on your
device to enhance site navigation, analyze site usage, and assist in our
marketing efforts. Our Privacy Policy
Cookies Settings Reject All Accept All Cookies



PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow All


MANAGE CONSENT PREFERENCES

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

SOCIAL MEDIA COOKIES

Social Media Cookies

These cookies are set by a range of social media services that we have added to
the site to enable you to share our content with your friends and networks. They
are capable of tracking your browser across other sites and building up a
profile of your interests. This may impact the content and messages you see on
other websites you visit. If you do not allow these cookies you may not be able
to use or see these sharing tools.

Back Button


COOKIE LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Reject All Confirm My Choices


We'd like to show you notifications for the latest news and updates.


AllowCancel